Navigation Links
Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
Date:4/14/2010

Merrimack Pharmaceuticals, Inc. announced today that Clet Niyikiza, Ph.D., Executive Vice President of Development, will present at the BioVisionAlexandria 2010 conference as part of the panel, titled Cancer Care and Prevention: Novel Approaches.

Cambridge, MA (PRWEB) April 14, 2010 -- Clet Niyikiza, Ph.D., Executive Vice President of Development at Merrimack Pharmaceuticals, Inc., will present at the BioVisionAlexandria 2010 conference in Alexandria, Egypt.

The theme of this year’s fifth international biennial conference, put on by BioVision Alexandria, is New Life Sciences: Future Prospects. The goal of the conference is to get the greatest minds in industry, science, policy-making and civil society to identify and explore key areas in the field of life sciences that have the potential to serve a number of people across continents and cultures. Also featured in the conference is a Nobel Day where recipients of the Nobel Prize discuss the impact of their work and their future vision for the life sciences industry.

Dr. Niyikiza is speaking as part of a panel discussion in the Health portion of the conference which is built around the three major themes of Health, Food and Agriculture and Environment. The panel, titled Cancer Care and Prevention: Novel Approaches, takes place on Wednesday, April 14 from 3:30pm – 5:00pm.

About Merrimack
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

Contact: Kathleen Petrozzelli, Corporate Communications, 617-441-1043, Betsy Raymond Stevenson, 860-984-1424, RaymondStevenson Healthcare Comms

###

Read the full story at http://www.prweb.com/releases/2010/04/prweb3868554.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
2. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
3. UPDATE: Appeal of Lawsuit by Former Chief Executive Officer- Reinstated; and Sanctions Order Vacated
4. Appeal of Lawsuit by Former Chief Executive Officer- Reinstated; and Sanctions Order Vacated
5. BioSoteria eLearning Executive Michelle Flewell Selected for Accreditation Council
6. FMC Agricultural Products Executive Bob Trogele Speaks to the Iowa Agribusiness Showcase & Conference
7. Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board
8. Fibrocell Science, Inc. Names David Pernock Chief Executive Officer
9. Glycos Biotechnologies Appoints Chief Executive Officer
10. Biofuels Technology Leader Qteros Names Industry Veteran John McCarthy President and Chief Executive Officer
11. Marrone Bio Innovations Announces Two New Executive Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
(Date:4/29/2016)... 2016 Elekta is pleased to ... its industry-leading treatment planning software, is available for clinical ... version 5.11 provides significant performance speed enhancements ... up to four times faster than in previous versions ... gold standard Monte Carlo algorithm, ...
(Date:4/28/2016)... York, NY (PRWEB) , ... April 28, 2016 ... ... QuickSTAT has made significant investments in recruiting top industry experts, and expanding its ... Platform, which provides industry-leading tools for clients to manage their clinical trial projects. ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... screen mobile devices with fingerprint recognition for secure access, voice recognition for hands-free ... few ways consumers are interacting with biometrics technology today. But if they ...
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... ... Lamka, PhD to its Scientific Advisory Board. Dr. Lamka will assist PathSensors in ... pathogen detection. , PathSensors deploys the CANARY® test platform for the detection ...
Breaking Biology Technology:
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):